HOPHF (Hemogenyx Pharmaceuticals) Cash per Share: $0.35 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HOPHF Hemogenyx Pharmaceuticals PLC HOPHF
25 GF Score
Price $2.33
! 2 Warning Signs
View Full Analysis

What is Hemogenyx Pharmaceuticals Cash per Share?

Hemogenyx Pharmaceuticals HOPHF 25 Cash per Share is $0.35 as of Dec. 2025. GuruFocus rates HOPHF with a GF Score™ of 25/100. The stock has 2 warning signs investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Hemogenyx Pharmaceuticals's Cash per Share for the quarter that ended in Dec. 2025 was $0.35.

Hemogenyx Pharmaceuticals  (OTCPK:HOPHF) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Hemogenyx Pharmaceuticals Cash per Share Related Terms

Hemogenyx Pharmaceuticals Cash per Share Historical Data

* Premium members only.

The historical data trend for Hemogenyx Pharmaceuticals's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hemogenyx Pharmaceuticals Cash per Share Chart

Hemogenyx Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.72 1.26 0.54 0.06 0.35

Hemogenyx Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.54 0.62 0.06 0.07 0.35
HOPHF
25GF Score
Hemogenyx Pharmaceuticals PLC HOPHF
Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hemogenyx Pharmaceuticals Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Hemogenyx Pharmaceuticals's Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=2.123/6.04
=0.35

Hemogenyx Pharmaceuticals's Cash per Share for the quarter that ended in Dec. 2025 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=2.123/6.04
=0.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash per Share →
What does a Cash per Share of $0.35 mean?
Hemogenyx Pharmaceuticals (HOPHF) has a Cash per Share of $0.35 as of Dec. 2025. Cash per share is the per-share value of a company's available cash. View historical data for Hemogenyx Pharmaceuticals and its competitors.
Is Hemogenyx Pharmaceuticals' Cash per Share too high?
Hemogenyx Pharmaceuticals' current Cash per Share is $0.35. Overall, Hemogenyx Pharmaceuticals has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Hemogenyx Pharmaceuticals' Cash per Share compare to VRTX and REGN?
Hemogenyx Pharmaceuticals' Cash per Share of $0.35 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash per Share for a Biotechnology company?
A good Cash per Share depends on the Biotechnology industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash per Share mean?
A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for Hemogenyx Pharmaceuticals and its competitors. Hemogenyx Pharmaceuticals's current Cash per Share is $0.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemogenyx Pharmaceuticals stock overvalued right now?
Hemogenyx Pharmaceuticals (HOPHF) has a current Cash per Share of $0.35. The current Cash per Share is $0.35. Hemogenyx Pharmaceuticals' overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash per Share calculated?
Cash per Share is calculated from a company's financial statements. For Hemogenyx Pharmaceuticals (HOPHF), the current Cash per Share is $0.35 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hemogenyx Pharmaceuticals Business Description

Other Exchanges HEMO:UK
Address 6 Heddon Street, London, GBR, W1B 4BT
Hemogenyx Pharmaceuticals PLC is clinical-stage biotechnology focused on the discovery, development and commercialisation of treatments relating to the treatment of blood cancers, certain solid cancers, autoimmune diseases, and viral infections. The products under development are designed to address a range of problems that occur with current standard of care treatments. The Group has one reportable segment, the discovery, development, and commercialisation of treatments relating to blood and immune system disorders and viral infections, and administrative functions in the United Kingdom. It has its presence in United Kingdom; and United States.
25GF Score

Get the complete analysis for HOPHF

Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.33
Price